Servier Completes Edgewise Muscular Dystrophy Acquisition | Lucid Diligence Brief
Servier Completes the Edgewise Muscular Dystrophy Acquisition and Adds…
United Therapeutics’ Thymmune acquisition | Lucid Diligence Brief
United Therapeutics adds Thymmune’s iPSC thymic-cell platform to its…
Insilico Takeda AI Drug Discovery Deal | Lucid Diligence Brief
Insilico and Takeda test whether Pharma.AI can convert discovery speed into…
Innovent-Lilly Verzenios China Commercialization | Lucid Diligence Brief
Innovent takes mainland China commercial responsibility for Verzenios as Lilly…
Merck KGaA Bio-Techne Deal | Lucid Diligence Brief
Merck KGaA’s US$11.3bn Bio-Techne acquisition tests workflow depth, integration…
AbbVie's Apogee Acquisition Valued at $10.9B. | Lucid Diligence Brief
AbbVie’s Apogee deal adds zumilokibart and asthma assets as immunology growth…
DermaSensor AI dermatology devices | Lucid Diligence Brief
AI dermatology devices are advancing beyond validation studies as DermaSensor…
Lucid Diligence Brief: AlzeCure Pharma Collaboration and Out-Licensing Agreement with Eli Lilly
Lucid Diligence Brief: AlzeCure Pharma Collaboration and Out-Licensing…
Nurix Roche Bexobrutideg Deal | Lucid Diligence Brief
Roche’s collaboration with Nurix turns bexobrutideg into a multi-indication BTK…
Ascidian and Lilly $1.9B Deal for Kidney RNA Editing | Lucid Diligence Brief
Ascidian and Lilly $1.9B collaboration tests whether RNA exon editing can move…
Servier Edgewise Sevasemten Deal | Lucid Diligence Brief
Servier’s Edgewise acquisition puts sevasemten’s Becker muscular dystrophy data…
Lucid Diligence Brief: Olema OP-3136 and Bayer Darolutamide Deal
Lucid Diligence Brief: Olema expands OP-3136 into metastatic…